These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 15746047)

  • 1. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
    Heimberger AB; Hlatky R; Suki D; Yang D; Weinberg J; Gilbert M; Sawaya R; Aldape K
    Clin Cancer Res; 2005 Feb; 11(4):1462-6. PubMed ID: 15746047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
    Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural history of EGFR and EGFRvIII in glioblastoma patients.
    Heimberger AB; Suki D; Yang D; Shi W; Aldape K
    J Transl Med; 2005 Oct; 3():38. PubMed ID: 16236164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme.
    Quan AL; Barnett GH; Lee SY; Vogelbaum MA; Toms SA; Staugaitis SM; Prayson RA; Peereboom DM; Stevens GH; Cohen BH; Suh JH
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):695-703. PubMed ID: 15936158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group.
    Chakravarti A; Seiferheld W; Tu X; Wang H; Zhang HZ; Ang KK; Hammond E; Curran W; Mehta M
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):318-27. PubMed ID: 15890570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.
    Cunningham MP; Essapen S; Thomas H; Green M; Lovell DP; Topham C; Marks C; Modjtahedi H
    Int J Oncol; 2005 Aug; 27(2):317-25. PubMed ID: 16010411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome.
    Etienne MC; Formento JL; Lebrun-Frenay C; Gioanni J; Chatel M; Paquis P; Bernard C; Courdi A; Bensadoun RJ; Pignol JP; Francoual M; Grellier P; Frenay M; Milano G
    Clin Cancer Res; 1998 Oct; 4(10):2383-90. PubMed ID: 9796969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
    Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
    Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae.
    Abulrob A; Giuseppin S; Andrade MF; McDermid A; Moreno M; Stanimirovic D
    Oncogene; 2004 Sep; 23(41):6967-79. PubMed ID: 15273741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifocal glioblastoma multiforme: prognostic factors and patterns of progression.
    Showalter TN; Andrel J; Andrews DW; Curran WJ; Daskalakis C; Werner-Wasik M
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):820-4. PubMed ID: 17499453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
    Yoshimoto K; Dang J; Zhu S; Nathanson D; Huang T; Dumont R; Seligson DB; Yong WH; Xiong Z; Rao N; Winther H; Chakravarti A; Bigner DD; Mellinghoff IK; Horvath S; Cavenee WK; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2008 Jan; 14(2):488-93. PubMed ID: 18223223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
    Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological markers and prognosis in recurrent oral cancer after salvage surgery.
    Agra IM; Carvalho AL; Pinto CA; Martins EP; Filho JG; Soares FA; Kowalski LP
    Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):743-9. PubMed ID: 18645125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.
    Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H
    Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.